We are live on ! Find out more

CNSY

Cerenome

CNSY

Market cap $15.4M

2.03 USD

0.00

0%

At close Updated Sep 18, 4:00 PM EDT

Pre-market

After hours

2.01

-0.02

0.99%

1 day

0%

5 days

-11.74%

1 month

-34.09%

3 months

-51.67%

6 months

-65.59%

Year to date

-85.37%

1 year

-81.17%

5 years

-99.72%

10 years

-100%

About: Cerenome Inc is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The Company's CNSide Diagnostics platform supports the detection, molecular characterization, and longitudinal monitoring of CNS cancers through cerebrospinal fluid-based testing. Its therapeutic platform, REYOBIQ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation.

Employees: 28

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 92.9%

Negative 7.1%

Cerenome Appoints Samantha Fowlkes as Vice President and Head of Commercial Sales, CNSide Diagnostics Division

HOUSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), today announces the appointment of Samantha Fowlkes as Vice President Head of Commercial Sales. Samantha will lead the commercial expansion of CNSide®, strengthening relationships across the oncology and pathology communities, and accelerate adoption of the CNSide platform by physicians and health systems.

Cerenome Appoints Samantha Fowlkes as Vice President and Head of Commercial Sales, CNSide Diagnostics Division

Cerenome Announces Up to $20 Million Financing Facility with Royalty-Based Repayment

Capital will support continued CNSide® commercial scale-up and development Initial tranche of funding provided at closing with future tranches linked to milestones Forecasted cash runway now into 2028 HOUSTON, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), a CNS oncology company advancing an integrated platform of precision diagnostics, targeted therapeutics, and artificial intelligence, today announced that it has entered into a financing agreement with 3i, LP (“3i Fund”) for a senior secured facility of up to $20 million with royalty-based repayments.

Cerenome Announces Up to $20 Million Financing Facility with Royalty-Based Repayment

Cerenome Highlights Presentations at the 2026 SNO/ASCO CNS Metastases Conference Demonstrating Progress in Both Therapeutics and Diagnostics Business Lines

Cerenome highlights SNO/ASCO data showing REYOBIQ CSF distribution and safety, and CNSide's potential to reduce monthly LM treatment costs by up to 47%.

Cerenome Highlights Presentations at the 2026 SNO/ASCO CNS Metastases Conference Demonstrating Progress in Both Therapeutics and Diagnostics Business Lines

Zacks Investment Research

Cerenome (CNSY) Reports Q2 Loss, Misses Revenue Estimates

Cerenome (CNSY) came out with a quarterly loss of $1.31 per share versus the Zacks Consensus Estimate of a loss of $0.96. This compares to a loss of $0.25 per share a year ago.

Cerenome (CNSY) Reports Q2 Loss, Misses Revenue Estimates

Cerenome Reports Second Quarter 2026 Financial Results and Business Update

HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence, today announced financial results for the second quarter ended June 30, 2026, and provided an overview of recent and upcoming business highlights.

Cerenome Reports Second Quarter 2026 Financial Results and Business Update

Cerenome Launches as an Integrated CNS Oncology Company

HOUSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today announces that its corporate rebrand to Cerenome will be completed as scheduled. Effective August 3, 2026, the Company's name will become Cerenome, Inc. The Company's common stock will begin trading on the Nasdaq Capital Market under the new ticker symbol “CNSY,” effective market open on the same day.

Cerenome Launches as an Integrated CNS Oncology Company

Plus Therapeutics Announces Scientific Presentations and Sponsored Symposium at 2026 SNO/ASCO CNS Metastases Conference

HOUSTON, July 28, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a healthcare company developing and commercializing targeted therapeutics and diagnostics for central nervous system (“CNS”) cancers, today announced two posters highlighting its ReSPECT-LM clinical development program and CNSide® cerebrospinal fluid (“CSF”) diagnostic platform will be presented at the 2026 Society for Neuro-Oncology/American Society of Clinical Oncology (“SNO/ASCO”) CNS Metastases Conference, being held August 13–15, 2026, in Boston, Massachusetts. The Company and its wholly owned subsidiary, CNSide Diagnostics, LLC, will also host a sponsored symposium titled “Redefining the Management of Leptomeningeal Metastases: Integrating Diagnostics, Molecular Insights, and Emerging Therapies” on Thursday evening, August 13, 2026.

Plus Therapeutics Announces Scientific Presentations and Sponsored Symposium at 2026 SNO/ASCO CNS Metastases Conference

Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

HOUSTON, July 21, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV ) (“Plus” or the “Company”), announced today that it has signed a regional agreement with Medical Mutual effective July 1, 2026, covering approximately 1.2 million people throughout Ohio and Kentucky, to provide the CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay. This brings CNSide CSF TCE assay total contracted coverage to approximately 127 million people.

Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay Platform

Collaboration expected to deliver hundreds of DNA and RNA biomarkers from a single CSF specimen — directly aligned with the updated NCCN Guidelines® (Version 2.2026), which now recognize CSF circulating tumor cells alongside tumor-derived DNA and broaden the leptomeningeal treatment algorithm from “CSF cytology” to “CSF analysis” Collaboration expected to deliver hundreds of DNA and RNA biomarkers from a single CSF specimen — directly aligned with the updated NCCN Guidelines® (Version 2.2026), which now recognize CSF circulating tumor cells alongside tumor-derived DNA and broaden the leptomeningeal treatment algorithm from “CSF cytology” to “CSF analysis”

Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay Platform

Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases Monitoring

Updated NCCN language continues to support CSF analysis in the diagnosis and management of leptomeningeal metastases, including CSF cytology follow-up every 4 to 8 weeks for patients receiving intrathecal therapy, to enable longitudinal patient monitoring Updated NCCN language continues to support CSF analysis in the diagnosis and management of leptomeningeal metastases, including CSF cytology follow-up every 4 to 8 weeks for patients receiving intrathecal therapy, to enable longitudinal patient monitoring

Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases Monitoring

See News Rankings

Price charts implemented using Lightweight Charts™